For metastatic castration-resistant prostate cancer (mCRPC), docetaxel was the first drug to show an overall survival (OS) benefit in two large phase III trials published in 2004 [1,2]. Until 2010 when cabazitaxel and abiraterone were shown to prolong survival after first-line docetaxel chemotherapy, physicians had very little treatment options to offer for men with mCRPC, and docetaxel re-challenge was frequently used despite the lack of prospective trial data [3,4].
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2BVhnJ8
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Bromodomain proteins function as epigenetic readers that recognize acetylated histone tails to facilitate the transcription of t...
-
Objectives To optimise medical students’ early clerkship is a complex task since it is conducted in a context primarily organised to take ca...
-
Abstract Purpose Overcoming the flaws of current data management conditions in head and neck oncology could enable integrated informatio...
-
C. Julian Chen'Correspondence information about the author C. Julian ChenEmail the author C. Julian Chen, Donald A. Miller DOI: https://...
-
ACS Nano DOI: 10.1021/acsnano.7b00032 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2lNPpuk via...
-
Abstract Polychlorinated biphenyls (PCBs), a group of 209 congeners that differ in the number and position of chlorines on the biphenyl rin...
-
1 abqls-210rm.html Read the latest Journal of Clinical Neurophysiology - Vol. 37, No. 1, January 2020.eml 2 agx3v-nxz96.html Read the late...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου